Tag: Intact vascular

Identifying and repairing dissections that matter

 Marianne Brodmann (Graz, Austria) quizzes Michael Lichternberg (Arnsberg, Germany) at LINC 2019 on his choice of tools to identify and repair dissections in both...

Tack Endovascular System launches in the EU with first commercial use...

The first commercial use of the Tack Endovascular System (Intact Vascular) has taken place in multiple hospitals within Germany. A novel therapy for dissection...
enrolment

TOBA II BTK clinical trial completes enrolment

The Tack Optimised Balloon Angioplasty II below-the-knee (TOBA II BTK) clinical trial has successfully completed enrolment, ahead of schedule. This study, sponsored by Intact...

TOBA II shows repairing dissections after angioplasty “clearly augments” outcomes for...

Thomas Zeller (Bad Krozingen, Germany) delves into data and design of the TOBA II (Tack Optimized Balloon Angioplasty II) trial with principal investigator William...

TOBA II trial meets primary and secondary endpoints at one-year

The Tack Optimized Balloon Angioplasty II (TOBA II) clinical trial has successfully achieved both primary and secondary endpoints. One year results from the TOBA...

Intact Vascular announces presentation of TOBA II pivotal data

Intact Vascular has announced that data from its Tack Optimized Balloon Angioplasty (TOBA) II pivotal study will be presented as a late-breaking clinical trial...

Tack Endovascular System secures US$20 million in premarket approval funding

Intact Vascular, a developer of medical devices for minimally invasive peripheral vascular procedures, has announced that it closed a Series C financing totaling US$20 million....

TOBA BTK trial study publishes one-year results for Tack endovascular system

The TOBA BTK (Tack Optimized Balloon Angioplasty Below the Knee) clinical trial results have recently been published in Catheterization and Cardiovascular Intervention. The multicentre...

TOBA single-centre trial shows 24-month patency rate of 87.5%

Positive single-centre 24-month results from Intact Vascular’s TOBA (Tack optimised balloon angioplasty) clinical study were presented at the 2017 VEITHsymposium 2017 (14–18 November, New York City, USA) by...

Intact Vascular announces enrolment of first European patient in TOBA II...

Intact Vascular’s TOBA II BTK (Tack optimized balloon angioplasty II below the knee) clinical trial has commenced enrolment in Europe, with the first patient treated by Marianne Brodmann and Peter Reif...

FDA approves six-month primary endpoint for Tack endovascular system in below-the-knee...

The US Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint in Intact Vascular’s TOBA II...

Intact Vascular appoints Howard Rosen as vice president of marketing and...

Howard Rosen has joined Intact Vascular’s executive management team as vice president of marketing and business development. In this position, Rosen will lead the...

Intact Vascular completes enrolment in TOBA II clinical trial

Intact Vascular’s TOBA II (Tack optimized balloon angioplasty II) clinical trial has completed enrolment. A total of 210 patients have been enrolled in TOBA II at 33 sites...

Using the Tack endovascular system to treat vessel dissection

At LINC 2017 Vascular News spoke to Peter Schneider (Kaiser Foundation Hospital, Honolulu, Hawaii, USA) about the Tack endovascular system (Intact Vascular), an implant designed to repair...

TOBA II BTK clinical trial commences enrolment with first implant of...

Intact Vascular’s TOBA II BTK (Tack optimised balloon angioplasty II below the knee) clinical trial has commenced enrolment, with the first patient treated by Joseph Cardenas at Yuma Regional Hospital and...

Intact Vascular closes on additional funding to advance development of Tack...

Current Intact Vascular investors—New Enterprise Associates, Quaker Partners and HIG BioHealth Partners—have exercised their right to invest additional capital as part of the company’s...

TOBA study results demonstrate 76.4% 12-month primary patency and 89.5% freedom...

The one-year results from Intact Vascular’s Tack Optimized Balloon Angioplasty (TOBA) clinical study have been published in the Journal of Vascular Surgery. The TOBA study...